Latest news with #bronchiectasis
Yahoo
23-05-2025
- Health
- Yahoo
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - Pipeline Innovations Expected to Add $1.8 Billion in Bronchiectasis Market Sales
Explore the latest bronchiectasis market report for the 8MM (US, France, Germany, Italy, Spain, UK, Japan, China) with insights into non-CF bronchiectasis. Discover market growth trends, forecasted to reach $3.7 billion by 2033, with a 9.8% CAGR. Gain competitive analysis and pipeline insights for strategic advantage. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Bronchiectasis: Opportunity Assessment and Forecast - Update" has been added to offering. The report delivers a comprehensive overview of bronchiectasis, highlighting epidemiology, symptoms, and management market revenue for bronchiectasis treatments is annualized, including therapy costs per patient and treatment patterns from 2023 to 2033. From a market perspective, the bronchiectasis treatment landscape was estimated at $1.5 billion in 2023. Forward-looking projections predict robust growth with a compound annual growth rate (CAGR) of 9.8%, aiming to reach $3.7 billion by 2033. Emerging pipeline agents are expected to play a pivotal role, contributing an additional $1.8 billion in sales. The expansive bronchiectasis market report spans 8 major markets: the US, France, Germany, Italy, Spain, UK, Japan, and China, offering in-depth insights and forecasts through to 2033. Supported with an Excel-based forecast model, the report provides invaluable data and projections to navigate this growing sector. Bronchiectasis poses significant clinical challenges due to damage and abnormal dilation in the bronchi, leading to chronic lung issues like inflammation and persistent bacterial infections. The report exclusively focuses on non-cystic fibrosis (non-CF) bronchiectasis, examining patient demographics and clinical symptoms which include persistent cough, sputum production, and recurrent chest infections among others. Scope Key discussions feature strategic competitor assessments, unmet needs, and the landscape of clinical trials impacting the bronchiectasis market. An in-depth pipeline analysis explores new trends and developmental mechanisms in bronchiectasis therapeutics. Noteworthy candidates in advanced clinical phases are detailed. Competitive analysis in the global bronchiectasis market offers insights into industry trends, market drivers, and potential challenges, each meticulously researched for qualitative insights. Reasons to Buy Leverage insights to craft in-licensing and out-licensing strategies, focusing on current pipeline strengths and innovation. Shape business tactics by understanding the evolving trends and drivers in the bronchiectasis therapeutics landscape. Enhance revenue lines by aligning with key trends, innovative technology, and competitive market segments that define the future landscape. Strengthen sales and marketing approaches by dissecting competitor performance and understanding the competitive ecosystem. Capitalize on emerging players with robust portfolios for strategic advantage and growth. Track the trajectory of drug sales within the eight-market bronchiectasis space from 2023 to 2033 for informed decision-making. Optimize marketing efforts by targeting specific market segments that offer lucrative consolidation and partnership opportunities. Key Topics Covered: 1. Preface1.1. Contents1.2. Abbreviations1.3. Summary of Updates1.4. Related Reports2. Executive Summary3. Disease Overview3.1. Overview of Bronchiectasis3.2. Bronchiectasis SWOT Analysis3.3. Pathophysiology of Bronchiectasis3.4. Classification of Bronchiectasis4. Epidemiology4.1. Total Prevalent Cases of Bronchiectasis4.2. Age-Specific Trends in Diagnosed Prevalent Cases4.3. Sex-Specific Diagnosed Prevalent Cases4.4. Diagnosed Prevalent Cases By Severity4.5. Sources and Methodology5. Current Treatment Options5.1. Treatment Paradigm5.2. Marketed Products5.3. Product Profiles6. Unmet Needs and Opportunities6.1. Unmet Needs in Bronchiectasis6.2. Increased Awareness and Education6.3. Improved Diagnostic Methods6.4. Lack of Approved Therapies6.5. Targets for Improved Therapies7. R&D Strategies7.1. Trends in Clinical Trial Design7.2. Trends in Deal-Making8. Pipeline Assessment8.1. Bronchiectasis Pipeline Overview8.2. Late-Stage Pipeline Agents8.3. Product Profiles9. Market Outlook9.1. Bronchiectasis Market Forecast9.2. Market Drivers and Barriers10. Appendix Competitive Landscape Insmed Joincare Renovion Sanofi Regeneron Armata Boehringer Ingelheim Chiesi Farmaceutici Haisco Pharmaceutical Metagone Biotech SolAeroMed Suzhou Regend Therapeutics CSL BioAegis Therapeutics AstraZeneca Reistone Biopharma Shanghai Fosun Pharmaceutical (Group) Co Ltd For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Telegraph
10-05-2025
- Health
- Telegraph
British scientists invent new treatment for disease suffered by Pope Francis
British scientists have developed a world-first treatment for an incurable condition that contributed to the Pope's death. Pope Francis was suffering from a chronic lung condition, called multiple bronchiectasis, which along with pneumonia left him hospital-bound for more than a month prior to his death. The 88-year-old officially died of a stroke, coma, and irreversible cardiovascular collapse, but the Vatican's death certificate noted his chronic lung issues, high blood pressure and type II diabetes, as conditions contributing to his ill-health and passing. However, a drug called brensocatib, manufactured by US firm Insmed, is set to become the first-ever treatment for bronchiectasis, just weeks after the pope was hospitalised with it as his health began to significantly deteriorate. The inflammatory condition is caused by white blood cells that are meant to fight infection, instead attacking the lung and 'eating away' at it. People with the condition often suffer from 'flare-ups' that cause coughing fits, pain and chest infection or pneumonia-like symptoms, that can become fatal. The new drug, which is the culmination of 15 years of work by experts at the University of Dundee, works by switching off the enzymes that are damaging the lungs. The research published in the New England Journal of Medicine has revealed patients taking the therapy experienced fewer symptoms, such as phlegm and coughing, as well as flare-ups. The largest trial into the disease ever conducted found those receiving the drug had 20 per cent fewer flare-ups on average, while it also slowed down the progression of the disease by 50 per cent, and reduced symptoms. When it was revealed that Pope Francis had been hospitalised with a 'complex lung infection', the complication was his pre-existing condition of bronchiectasis. It is thought he developed the condition after having part of his lungs removed as a young man because of a severe infection such as pneumonia. Prof James Chalmers, the lead researcher and a professor in respiratory medicine at the University of Dundee, said it was 'quite common for people who have bronchiectasis'. 'It often starts in childhood. You get a bad chest infection in childhood, or something severe, like whooping cough, it damages an area of the lung, and now you have bronchiectasis for the rest of your life,' he said. 'And so the pope, according to what was announced by the Gemelli Hospital was that pneumonia was associated with bronchiectasis, and that's what happens with people when they get bronchiectasis, they get these flare-ups, which are like pneumonia, they get infections with bugs,' he said. 'So what happened to the pope is, unfortunately, quite typical of the sort of natural history of this disease.' 'A major breakthrough' Prof Chalmers said the results were a 'major breakthrough for this disease because at the moment there's no approved treatment', with patients typically given antibiotics to treat infections that they can become resistant to over time. He said the condition goes undiagnosed in a lot of people, or misdiagnosed in others, with doctors often confusing it with asthma or other lung conditions. The number of cases has soared by 40 per cent in recent years as diagnostic technology improves and around a third of people receiving a diagnosis had previously been told they had asthma or something else, according to a survey. Bronchiectasis potentially affects hundreds of thousands of people across Europe, causing some 1,500 deaths each year in the UK. Insmed is seeking regulatory approval for brensocatib in the US, followed by applications in Europe and Japan. It is understood approval on the NHS will be sought next year.
